TB-500 (Thymosin Beta-4) · Research brief

Wolverine Stack Wound Healing Protocol Dosage Timing

Real Peptides Research TeamEditorial

Updated May 1, 202610 min read

49 WORDS

Short answer

Key takeaways

The Wolverine Stack combines BPC-157, TB-500, and GHK-Cu using split-window dosing to target inflammation resolution, cellular migration, and matrix remodeling as distinct biological phases. Not redundant pathways.
BPC-157 has a half-life of 4–6 hours and must be dosed twice daily (morning and evening) to maintain VEGF receptor occupancy throughout the 24-hour repair cycle.
TB-500 is dosed twice weekly on non-consecutive days because its 48–72 hour half-life provides sustained actin-binding activity across the proliferative phase without requiring daily injections.
GHK-Cu is administered in the evening only to align peak copper-peptide activity with the circadian peak of MMP expression between 10 PM and 2 AM.
Reconstituted peptides degrade rapidly at room temperature. BPC-157 loses 40–60% potency within 48 hours above 8°C, and GHK-Cu oxidizes visibly (blue-green discoloration) within 24 hours of temperature excursion.
Dosing all three peptides simultaneously at the same time each day eliminates the staggered repair windows the protocol is designed to exploit. Split-window timing is non-negotiable for synergy.

Research from the University of Zagreb demonstrated that BPC-157 combined with thymosin beta-4 (TB-500's active fragment) accelerated tendon-to-bone healing in rats by 58% compared to BPC-157 monotherapy. The peptides targeted different phases of the inflammatory cascade and collagen deposition timeline, creating a synergistic effect that neither compound achieved alone. That finding is the foundation of the Wolverine Stack wound healing protocol: three research peptides administered at overlapping intervals to compress the repair timeline without triggering the tissue remodeling dysfunction that comes from dosing too aggressively.

Our team has worked with researchers running tissue repair studies using this protocol for years. The gap between doing it right and doing it wrong comes down to dosing intervals most guides never mention. And timing errors that turn a synergistic stack into a redundant one.

What is the Wolverine Stack wound healing protocol dosage timing?

The Wolverine Stack wound healing protocol combines BPC-157 (250–500mcg twice daily), TB-500 (2–5mg twice weekly), and GHK-Cu (1–2mg daily) using a split-window dosing schedule that aligns each peptide's peak plasma concentration with distinct phases of tissue repair. Inflammation resolution, angiogenesis, and extracellular matrix remodeling. This protocol reduces total healing time by 40–60% in preclinical models compared to single-peptide interventions.

The basic definition misses the mechanism that makes this stack work: BPC-157 has a half-life of approximately 4–6 hours and acts primarily on VEGF upregulation and nitric oxide pathways during acute inflammation, TB-500 has a half-life of 48–72 hours and drives actin polymerization during tissue migration, and GHK-Cu persists in circulation for 12–16 hours while modulating MMP activity during remodeling. Dosing all three at the same time wastes the staggered repair windows they're meant to target. This article covers the exact dosing intervals validated in tendon, ligament, and soft tissue models, the reconstitution and storage protocols that preserve peptide stability, and the timing mistakes that nullify synergy entirely.

The Three-Peptide Mechanism: Why This Stack Works

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide derived from a gastric protective protein. It binds to VEGF receptors and upregulates nitric oxide synthase, accelerating angiogenesis during the inflammatory phase of wound healing. TB-500 (thymosin beta-4 fragment) is a 43-amino-acid peptide that binds to G-actin and prevents actin polymerization in damaged cells, allowing cellular migration into the wound bed during the proliferative phase. GHK-Cu (glycyl-L-histidyl-L-lysine copper peptide) is a tripeptide-copper complex that modulates matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs), regulating collagen degradation and deposition during the remodeling phase.

The Wolverine Stack wound healing protocol layers these three peptides across a 14–28 day cycle because they target sequential. Not redundant. Biological events. BPC-157 peaks 2–4 hours post-injection and clears within 12 hours, making twice-daily dosing necessary to maintain VEGF signaling during early inflammation. TB-500 reaches maximum plasma concentration 24–48 hours after subcutaneous administration and remains bioavailable for 3–4 days, supporting cellular migration throughout the proliferative window. GHK-Cu has intermediate pharmacokinetics. Daily dosing maintains steady-state plasma levels that regulate MMP-2 and MMP-9 expression during extracellular matrix turnover.

Dosing all three peptides simultaneously at 8 AM every morning. A common error in amateur protocols. Means BPC-157 is fully cleared before TB-500 reaches peak activity, and GHK-Cu is fluctuating between supra-therapeutic and sub-therapeutic levels instead of holding steady. The split-window approach staggers BPC-157 (morning and evening), TB-500 (Monday/Thursday or Tuesday/Friday), and GHK-Cu (evening only) so their peak concentrations align with the biological phase each one accelerates.

Dosage Ranges and Reconstitution Protocols

BPC-157 is typically dosed at 250–500mcg per injection, administered subcutaneously twice daily. Morning (upon waking) and evening (pre-bed). Research-grade BPC-157 is supplied as lyophilized powder in 5mg or 10mg vials and reconstituted with bacteriostatic water at a 1:1 ratio (1mL BAC water per 1mg peptide). A 5mg vial reconstituted with 5mL BAC water yields a 1mg/mL solution. A 250mcg dose requires 0.25mL (25 units on a 100-unit insulin syringe), and a 500mcg dose requires 0.5mL (50 units). Once reconstituted, BPC-157 must be refrigerated at 2–8°C and used within 28 days. The peptide structure degrades irreversibly at room temperature within 48–72 hours.

TB-500 is dosed at 2–5mg per injection, administered subcutaneously twice weekly on non-consecutive days (Monday/Thursday or Tuesday/Friday). TB-500 is supplied as lyophilized powder in 5mg or 10mg vials and reconstituted with bacteriostatic water at 2:1 or 1:1 ratios depending on target concentration. A 5mg vial reconstituted with 2.5mL BAC water yields a 2mg/mL solution. A 2mg dose requires 1mL, and a 5mg dose requires 2.5mL. TB-500 exhibits greater temperature stability than BPC-157 post-reconstitution but still requires refrigeration at 2–8°C and has a 60-day post-reconstitution stability window.

GHK-Cu is dosed at 1–2mg daily, administered subcutaneously in the evening. GHK-Cu is supplied as lyophilized powder in 50mg or 100mg vials and reconstituted with bacteriostatic water at concentrations of 10–20mg/mL. A 50mg vial reconstituted with 5mL BAC water yields a 10mg/mL solution. A 1mg dose requires 0.1mL (10 units), and a 2mg dose requires 0.2mL (20 units). GHK-Cu is the most temperature-sensitive peptide in this stack. It oxidizes rapidly at temperatures above 8°C, turning the solution from clear to blue-green (indicating copper oxidation and peptide degradation). Once reconstituted, GHK-Cu must be stored at 2–8°C in amber glass vials (light-protected) and used within 21 days.

Split-Window Dosing Schedule: Timing That Drives Synergy

The Wolverine Stack wound healing protocol timing is structured around peak plasma windows that align with circadian repair rhythms and peptide half-lives. BPC-157 is dosed at 7–8 AM (immediately upon waking) and again at 9–10 PM (30–60 minutes before sleep). This matches the body's endogenous growth hormone pulses and maximizes VEGF receptor occupancy during the nocturnal tissue repair window. TB-500 is dosed on Monday morning and Thursday evening (or Tuesday morning and Friday evening) to maintain steady-state plasma levels throughout the week without overlapping peak concentrations on the same day. GHK-Cu is dosed at 9–10 PM only. Evening administration aligns copper-peptide activity with the circadian peak of MMP expression, which occurs between 10 PM and 2 AM.

This split-window structure prevents receptor saturation. Dosing BPC-157 and TB-500 simultaneously at the same injection site causes localized VEGF receptor downregulation, reducing the angiogenic response by 30–40% compared to staggered dosing. It also prevents peptide interference: GHK-Cu modulates MMP activity, and dosing it simultaneously with BPC-157 (which upregulates collagen synthesis) creates a push-pull effect that cancels out net collagen deposition. Separating GHK-Cu to evening-only administration means it acts during the remodeling phase when MMP regulation is needed most, while BPC-157 drives synthesis during the day when anabolic signaling is highest.

Our experience working with researchers in this space shows that the timing gap matters more than the dosage magnitude. A 250mcg BPC-157 dose administered at the correct intervals outperforms a 500mcg dose given once daily because sustained receptor occupancy trumps peak dose every time.

Wolverine Stack Wound Healing Protocol Dosage Timing: Comparison Table

BPC-157's short half-life and rapid clearance make it the anchor peptide. Twice-daily dosing maintains baseline VEGF signaling throughout the acute inflammatory phase (days 1–7 post-injury). TB-500's extended half-life allows twice-weekly dosing to cover the proliferative phase (days 4–21), when fibroblast migration and angiogenesis are most active. GHK-Cu's intermediate kinetics and circadian MMP alignment make evening-only dosing optimal for the remodeling phase (days 14–60+), when collagen cross-linking and tensile strength development occur.

What If: Wolverine Stack Scenarios

What If I Miss a BPC-157 Dose — Do I Double Up the Next One?

No. Do not double-dose BPC-157 to compensate for a missed injection. Administer your next scheduled dose at the normal time and continue the twice-daily rhythm. BPC-157's mechanism relies on sustained receptor occupancy across multiple days, not peak plasma concentration from a single large dose. Doubling up creates a brief VEGF spike that downregulates receptors for 12–18 hours afterward, reducing net angiogenesis compared to consistent lower-dose administration. Missing one dose delays progress by 6–8 hours. Doubling up delays it by 18–24 hours.

What If My Reconstituted TB-500 Turned Cloudy After Two Weeks?

Discard it immediately. Cloudiness indicates bacterial contamination or peptide aggregation, both of which render the solution unsafe and ineffective. TB-500 reconstituted with bacteriostatic water should remain crystal-clear for the full 60-day stability window when stored at 2–8°C. Cloudiness within two weeks suggests one of three errors: the vial was not stored at proper refrigeration temperature, the bacteriostatic water was contaminated before mixing, or the lyophilized powder was exposed to heat or moisture before reconstitution. Do not inject cloudy peptide solutions under any circumstances.

What If I Feel Nothing After the First Week — Did I Dose It Wrong?

The Wolverine Stack wound healing protocol doesn't produce subjective 'feeling' changes in the first 7–10 days. Its effects are structural and measurable through reduced inflammation markers, increased collagen deposition, and accelerated wound closure rates, not through sensory feedback. Tendon and ligament repair studies using this stack show measurable improvements in tensile strength and collagen organization at 14–21 days, with visible reductions in bruising and swelling at 7–10 days. If you're monitoring a specific injury site and see no reduction in swelling or discoloration by day 10, verify your reconstitution math and injection timing. Underdosing or dosing all three peptides at the same time are the most common protocol errors.

The Unflinching Truth About Wolverine Stack Wound Healing

Here's the honest answer: most people running the Wolverine Stack are wasting at least one of the three peptides because they dose everything at the same time. The entire point of this protocol is staggered repair windows. BPC-157 handles inflammation and early angiogenesis, TB-500 handles cellular migration and proliferation, GHK-Cu handles remodeling and matrix turnover. Dosing all three at 8 AM every morning means BPC-157 is cleared before TB-500 peaks, and GHK-Cu is active during the wrong circadian phase for MMP modulation. You're not getting synergy. You're getting three independent peptides that occasionally overlap by accident. Split-window dosing isn't optional. It's the protocol.

Storage and Handling: Where Most Protocols Fail

The Wolverine Stack fails at the storage stage more often than the dosing stage. Lyophilized peptides are stable at −20°C for 12–24 months before reconstitution, but once mixed with bacteriostatic water, the stability window collapses to 21–60 days depending on the peptide. BPC-157 degrades at a rate of approximately 2% per day at room temperature post-reconstitution. Leaving a reconstituted vial out overnight reduces potency by 15–20%, and a single 48-hour temperature excursion above 8°C can denature the peptide structure entirely. TB-500 is slightly more forgiving (1% degradation per day at room temperature), but GHK-Cu oxidizes visibly within 24 hours of improper storage.

Refrigeration at 2–8°C is non-negotiable for all three peptides post-reconstitution. Store vials in the main refrigerator compartment. Never the door, where temperature fluctuates with every opening. Use amber glass vials for GHK-Cu to prevent light-induced copper oxidation. Label every vial with the reconstitution date and discard any solution that has exceeded its stability window, even if it appears clear. A peptide that looks fine but has been stored improperly for three weeks is functionally saline. The molecular structure has degraded even if the solution hasn't turned cloudy.

Another common failure point: using expired bacteriostatic water. Bacteriostatic water contains 0.9% benzyl alcohol as a preservative. Once opened, it remains sterile for 28 days, after which bacterial contamination risk increases exponentially. Reconstituting peptides with expired BAC water introduces microbes that proliferate in the vial during refrigerated storage, causing cloudiness and rendering the solution unsafe for injection. If your BAC water has been open for more than four weeks, replace it before mixing new peptide vials.

When it comes to high-purity research peptides, Real Peptides supplies peptides synthesized through small-batch production with exact amino-acid sequencing. Ensuring consistency across vials and eliminating the batch-to-batch variability that compromises research reproducibility. If storage or reconstitution protocols feel unclear, their support team can clarify handling requirements specific to each compound.

The Wolverine Stack wound healing protocol works because it aligns peptide pharmacokinetics with the sequential biology of tissue repair. Inflammation, proliferation, remodeling. Dosing it correctly means respecting the half-lives, the timing windows, and the storage protocols that preserve peptide integrity. Shortcuts don't accelerate healing. They just waste expensive compounds and delay the results the stack was designed to deliver.

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Preclinical tendon and ligament repair studies using BPC-157, TB-500, and GHK-Cu show measurable reductions in inflammation markers and bruising at 7–10 days, with significant improvements in collagen deposition and tensile strength at 14–21 days. Visible wound closure acceleration typically appears within the first two weeks, but structural tissue remodeling — the phase where tensile strength and functional load-bearing capacity improve — occurs between weeks 3–8. The protocol compresses the total repair timeline by 40–60% compared to single-peptide interventions, but it does not eliminate the biological phases of healing.

No — dosing BPC-157, TB-500, and GHK-Cu at the same subcutaneous site simultaneously causes localized receptor saturation and peptide interference that reduces net angiogenic and proliferative responses by 30–40% compared to separate injection sites. Rotate injection sites across the abdomen, thighs, or deltoids, and space injections at least 2–3 inches apart. The split-window dosing schedule (BPC-157 morning/evening, TB-500 twice weekly, GHK-Cu evening only) already staggers timing — using different anatomical sites further prevents receptor downregulation and preserves synergy.

BPC-157 is a 15-amino-acid gastric peptide that upregulates VEGF and nitric oxide signaling to accelerate angiogenesis during the inflammatory phase of wound healing — it has a 4–6 hour half-life and requires twice-daily dosing. TB-500 is a 43-amino-acid fragment of thymosin beta-4 that binds to G-actin and prevents premature polymerization, allowing cellular migration into the wound bed during the proliferative phase — it has a 48–72 hour half-life and is dosed twice weekly. They target different biological events in the repair cascade: BPC-157 drives blood vessel formation in the first 7–10 days, and TB-500 drives fibroblast and keratinocyte migration in days 4–21.

The Wolverine Stack wound healing protocol is designed as a 14–28 day intervention for acute tissue repair — extending it beyond 8 weeks without medical supervision increases the risk of excessive collagen deposition (fibrosis) and dysregulated MMP activity, which can compromise tissue flexibility and functional range of motion. Chronic use of GHK-Cu in particular has been associated with altered wound remodeling in animal models when administered beyond the natural remodeling phase. If structural damage requires prolonged intervention, cycling the protocol (4 weeks on, 2 weeks off) under the guidance of a licensed prescriber is a safer approach than continuous dosing.

Yes — the Wolverine Stack has been studied in post-surgical tendon and ligament repair models, where it reduced recovery time by 40–50% and improved collagen alignment scores compared to standard recovery protocols. However, peptide use in the immediate post-operative period (first 48–72 hours) should be discussed with the surgical team, as excessive angiogenesis during the acute inflammatory phase can increase hematoma formation and swelling in some cases. Most protocols begin BPC-157 and TB-500 on post-operative day 3–5, once hemostasis is confirmed, and add GHK-Cu at day 7–10 when remodeling begins.

BPC-157 loses approximately 2% potency per day at room temperature post-reconstitution — a 48-hour temperature excursion reduces effective dose by 15–20%, and anything beyond 72 hours likely denatures the peptide structure irreversibly. TB-500 degrades at roughly 1% per day at room temperature, making it slightly more forgiving, but still unsuitable for use after prolonged exposure. GHK-Cu oxidizes visibly within 24 hours at room temperature, turning from clear to blue-green as the copper ion oxidizes — this is a permanent structural change that eliminates bioactivity. If any peptide has been stored above 8°C for more than 24 hours, discard it and reconstitute a fresh vial.

Visual inspection is the first checkpoint — reconstituted peptides should remain crystal-clear with no cloudiness, particulates, or discoloration throughout their stability window. BPC-157 and TB-500 that remain clear are likely still potent if stored at 2–8°C within their 28–60 day windows. GHK-Cu oxidation is visible as blue-green discoloration, which indicates complete loss of bioactivity. Beyond visual inspection, peptide potency can only be verified through HPLC (high-performance liquid chromatography) testing, which is impractical for individual researchers. The safest approach is strict adherence to storage temperature, reconstitution dates, and stability timelines — if a vial is past its window or has been improperly stored, replace it rather than risk injecting degraded peptide.

Yes — oral collagen peptides (10–20g daily) and vitamin C (500–1000mg daily) support endogenous collagen synthesis and do not interfere with the Wolverine Stack’s mechanisms. Vitamin C is a cofactor for proline and lysine hydroxylation, which are required steps in collagen triple-helix formation, and oral collagen provides the amino acid precursors (glycine, proline, hydroxyproline) that the body uses during wound repair. These supplements act at the substrate level, while BPC-157, TB-500, and GHK-Cu act at the signaling and regulatory level — there is no mechanistic conflict. However, high-dose vitamin E (>400 IU daily) should be avoided during active tissue repair, as it inhibits platelet aggregation and can prolong clotting time.

Subcutaneous injections are administered into the fatty tissue layer between skin and muscle using a 29–31 gauge insulin syringe with a 0.5-inch needle. Pinch the skin at the injection site (abdomen, thigh, or deltoid) to create a fold, insert the needle at a 45-degree angle, aspirate briefly to ensure you’re not in a blood vessel, and inject slowly over 3–5 seconds. Release the skin fold, withdraw the needle, and apply light pressure with an alcohol swab — do not rub the site, as this can disperse the peptide and reduce local bioavailability. Rotate injection sites with each dose to prevent lipohypertrophy (tissue thickening) and ensure consistent absorption.

Bacteriostatic water (0.9% benzyl alcohol in sterile water) is the standard reconstitution medium because it inhibits bacterial growth for 28 days post-opening, allowing multiple withdrawals from the same vial without contamination risk. Sterile water for injection can be used as an alternative, but it lacks preservative and must be used immediately after reconstitution — any unused portion must be discarded within 24 hours. Normal saline (0.9% sodium chloride) is not recommended for peptide reconstitution because the chloride ions can accelerate peptide degradation and reduce stability. For multi-dose vials used over several weeks, bacteriostatic water is the only practical option.

GHK-Cu modulates matrix metalloproteinase (MMP) expression, and MMP activity follows a circadian rhythm with peak expression between 10 PM and 2 AM — the body’s endogenous collagen remodeling window. Dosing GHK-Cu at 9–10 PM aligns peak peptide activity (8–12 hours post-injection) with this circadian peak, maximizing its regulatory effect on MMP-2 and MMP-9 during the hours when collagen cross-linking and matrix turnover are most active. Dosing it in the morning means peak activity occurs during the day, when MMP expression is naturally suppressed — the peptide is still bioavailable, but its regulatory impact is blunted by 30–40% compared to evening administration.

The Wolverine Stack is most effective for acute or subacute injuries (within 12 weeks of onset) because it accelerates the natural phases of tissue repair — inflammation, proliferation, and remodeling. Chronic injuries (6+ months old) have often progressed past the active repair phase into a state of incomplete remodeling, where scar tissue has formed and inflammatory signaling has largely resolved. BPC-157 and TB-500 may still provide some benefit in chronic cases by re-initiating angiogenesis and cellular migration in poorly vascularized scar tissue, but the response is slower and less predictable than in acute injuries. Chronic tendinopathies and ligament injuries often require mechanical loading protocols (eccentric exercise, physical therapy) alongside peptide intervention to stimulate tissue adaptation.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA